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2212-0661/© 2016 The Author. Published by Elsevier B.Va b s t r a c ta r t i c l e i n f oKeywords: While genomics, and other omics, research is rapidly advancing in the US and Europe, progress has been slower
in less resourced countries. The imbalance has given rise to concern about whether the beneﬁts of these ad-
vances, namely new and better tests, treatments, risk identiﬁcation, and prevention strategies, will be shared
and available to those living in less resourced reaches of the globe. In effort to give voice to researchers, an infor-
mal survey about barriers to advancing translationalmedicinewas administered to attendees of the 11th Asia Pa-
ciﬁc Conference on Human Genetics, 2015, Hanoi. The overall goal of the surveywas to identify unmet needs and
rank their importance. Most attendees completed the survey. Not surprisingly funding is indicated as a major
need. Respondents reported that lack of bioinformatics and computational tools, trained data scientists and ac-
cess to datasets is creating a signiﬁcant lag behind better resourced regions. Results are intended to informefforts
to create a regional consensus statement of need. Such a regional statement could help funding organizations and
policy makers seeking to promote global genomics beneﬁt sharing.








Standardized dataParadigm shifts are occurring at all stages along the path to transla-
tional medicine, complicating the processwhile also creating exciting op-
portunities. Translational genomics is no longer simply a nebulous bridge
from bench research to bedside care with research only conducted in a
top down fashion involving studies that are done in secrecy, with little
reporting back to research participants. Patients are contributing more
to, as well as demanding more from, their clinical encounters and genet-
ic/genomic data is more easily ﬂowing between greater and less
resourced institutions. The opportunity to develop high impact solutions
that are focused on greater relevance to human health is also greater
than ever before. At the same time, there is no consensus as to what are
truly ‘best practices’ for handling issues of data management/integration,
ethics, patient empowerment roles, provider knowledge, etc. A shared
understanding of how best to proceed is key to establishing viable trans-
lational and precision medicine.
Genomics, and other omics research is rapidly advancing in the US
and Europe but such progress has been slower in less resourced coun-
tries (Tekola-Ayele and Rotimi, 2015). The imbalance has given rise to
concern about whether the beneﬁts of these advances, new and better
tests, treatments, risk identiﬁcation, and prevention strategies will be
shared and available to those living in less resourced reaches of the
globe (Dickenson, 2004; Chadwick and Wilso, 2004). An interest in
identifying challenges and opportunities for improvement in low
resourced countries is not new. Several international groupings have
undertaken to understand needs and impediments for implementing
translational medicine. Last year the U.S. National Human Genome. This is an open access article underResearch Institute and the U.S. National Academy ofMedicine convened
90 leaders of genomic medicine from the U.S. and 25 other countries
spanning 5 continents to identify regional capabilities and the current
state of implementation and opportunities for collaboration, in efforts
to identify speciﬁc differences between the ‘haves and have nots’. An
informal poll of attendees revealed that the majority of these countries
have specialized clinical genomic capabilities (cancer treatment, rare
disease diagnosis and microbial pathogen identiﬁcation) but lack capa-
bilities for newborn genomic sequencing, or RNA, metabolomics or
proteomic proﬁling. Of note, is that poll results were similar to those
in a 2012 survey (Manolio et al., 2013).
Ascertaining global challenges and opportunities for improvements
typically involves polling experts who can afford to travel to suchmeet-
ings. Non-expert researchers and clinicians are less often polled. The
opportunity to do just this presented itself last fall at the 11th Asia
Paciﬁc Conference on Human Genetics (APCHG 2015) last fall in
Hanoi, Vietnam, which was themed Genetics and Genomics: The
Path to Translational Medicine. The meeting, which occurs every
other year, offered the chance to learn about research and clinical
impediments as well as needs for achieving successful strategies
from researchers and clinicians in small as well as larger institutions
in Vietnam and surrounding countries.
In effort to give voice to researcher needs, aswell as clinicianneeds, a
short informal survey about barriers to advancing translational medi-
cine was administered to attendees. The overall goal of the survey was
to identify regional unmet needs and rank their importance. The pur-
pose was to use results to begin developing a regional consensus state-
ment that could help funding organizations and policy makers seeking
to promote global genomics beneﬁt sharing.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 2.What are the three greatest needs in the area of research?
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1. What do you view as the major regional/local impediments to
advancing translational medicine? (open question)
2. What are the top 3 needs? Choose only 3 of the following and rank
your choice 1st, 2nd and 3rd: Access to data, Funding, Trained data
scientists, patient engagement, seamless integration of genomic
and clinical data, or knowledgeable clinicians.
3. What are the 3 greatest research needs? Choose only 3 of the
following and rank your choices 1st, 2nd and 3rd: access to
datasets, bioinformatics/computational tools, data storage and
management, access to clinical data, need for standardized data,
ethical issues (consent and privacy), funding, data scientists
4. What are the 3 greatest clinical delivery needs? Choose only 3 of the
following and rank your choices 1st, 2nd and 3rd: genetic resources,
clinical decision support, provider education, ability to identify and
refer patients, or patient engagement.
5. What is important to emphasize in a consensus statement? (open
question)
60 attendees completed the survey. Responses were as follows.
In response to question 1, the vast majority of respondents reported
that resource limitations and lack of government support was the big-
gest barrier, followed by lack of knowledge and training, poor collabora-
tion, lack of acceptance of genomic health as a priority and data sharing.
Normative beliefs, lack of interest, patient engagement, regulation and
language barriers were also reported by a few. In regard to question 2,
the greatest need reported was funding (28), followed by trained data
scientists and access to data, with knowledgeable clinicians, a close
third (Fig. 1). While not surprising that funding would be identiﬁed as
the greatest need, it is perhaps noteworthy that the need for trained
data scientists and data access was deemed the next greatest need.
Beyond reﬂecting that the need for data is universal, this result suggests
a speciﬁc gap that with the help of experts in theWest and well-funded
training programs might well be readily ﬁlled.
In response to question 3, attendees reported that the greatest
unmet research need is funding (31), with bioinformatics/computational
tools and access to clinical data tied for second greatest need, and access
to datasets the third greatest need (Fig. 2). Access to clinical data, the
need for standardized data, and ethical issues were designated as greater
needs than data scientists. The low ranking of the need for data scientists
here conﬂictswith its higher rank as anoverall need inquestion1. Anum-
ber of different speculative explanations fare possible for this discrepancy,
such as the need to access and be able to work with data is greater than
the need for more data scientists, or the respondents presumed that
data scientists were subsumed in the need for data access or respondents
simply didn't understand the question correctly.
In response to question 4, attendees reported that clinical decision
support was the greatest unmet clinical delivery need, followed by pro-
vider education and access to genetic resources (Fig. 3). This resultFig. 1. What top three needs does your institution require to advance translational
medicine?suggests a deﬁned need for knowing how to integrate new genetic/ge-
nomic knowledge into clinical delivery. While the question did not dis-
tinguish between informatics/machine based or actual person-to-
person expert knowledge support, responses suggest that the beneﬁts
of genetic/genomic advances will not be optimally realized unless
knowledge about how to apply advancements in a clinical context is ob-
tained. This suggests both a need for translational research as well as
applied research designed to identify how best to integrate new
clinical knowledge.
Only 24 of 60 respondents answered question 5. Five respondents
indicated that a consensus statement should address important regional
differences amongst member countries. Four reported that de-identiﬁed
data should be shared. Three respondents reported that government
support and funding needs should be speciﬁed in such a document.
Two attendees reported that genomic education for clinicians and
patients was important to include in a consensus statement on need.
The remaining respondents reported a broad range of other vital factors;
speciﬁcally, the need to convince government that genomics is important
and that funding a genomics infrastructure is imperative, the need for
funding to train a genomics workforce, the need for individual disciplines
to collaborate, the need for global help with basic clinical research, the
need for affordable genetic and genomic tests, the need to design laws
and regulations to ensure the existence of public genomic health pro-
grams, and the need to train data scientists and the need to access both
data and new knowledge.
One relatively easy and immediate solution would be to create a
resource network within Asia Paciﬁc to connect regional experts and
related resources to researchers and data scientists in need. Online edu-
cational/training resources as well as the opportunity to connect with
experts for speciﬁc research advice could well serve both researchers
in training as well as translational researchers, and implementation
initiatives through knowledge transfer, collaborative problem-solving
and capacity building. Such a network can further beneﬁt researchersFig. 3.What are the three greatest needs in the area of clinical delivery?
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global initiatives designed to share approaches and lessons learned
towards accelerating the implementation of genomic medicine world-
wide, such as the Pan-Asia Paciﬁc Genome Initiative, TheGlobal Organiza-
tion for Bioinformatics Learning, Education and Training, the Asia-Paciﬁc
Bioinformatics Network, and various Centers for Global Health around
the world (Manolio et al., 2015; Ranganatha et al., 2012; Weitzel et al.,
2016; Attwood, et al., 2015; Daar et al., 2007).
In conclusion, this preliminary informal survey indicates that a
broad range of unmet infrastructure needs exist in the region, not
the least of which is funding and capacity building. Further research
is needed to better understand unmet needs and to engineer strate-
gic solutions. Creating an online regional network of experts and re-
sources that is connected to speciﬁc local areas of needs could help
jumpstart progress. Continued needs assessments and strategic
remedies can help ensuring that low resourced countries are suc-
cessful in research and clinical integration and thus able to realize
the beneﬁts of genetic/genomic advances.
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